Viatris Inc. has appointed Matthew J. Maletta as its new Chief Legal Officer, effective February 9, 2026. Maletta joins the company after a 12‑year tenure at Endo, where he served as Executive Vice President, Chief Legal Officer and Corporate Secretary, and after senior legal roles at Allergan, including oversight of the $70 billion Allergan‑Actavis transaction.
Brian Roman, the long‑time CLO who has guided Viatris and its predecessor Mylan for more than two decades, will remain on an advisory basis through April 1, 2026 to ensure a smooth transition. Roman’s continued involvement underscores the company’s commitment to continuity in its legal and regulatory functions.
Maletta’s appointment comes at a time when Viatris faces heightened regulatory scrutiny, including a recent $6.25 million settlement with Virginia over EpiPen pricing and an FDA warning related to its Indore manufacturing facility. His deep experience in pharmaceutical legal and compliance matters—particularly in complex mergers, spin‑offs and global regulatory compliance—positions Viatris to strengthen its legal and regulatory capabilities as it expands its product portfolio and navigates complex global markets.
The announcement was well received by investors, with Viatris’ stock rising 4.51 % on the day of the news. The positive market reaction reflects confidence in the new leadership’s ability to manage legal risks and support the company’s upcoming Q4 and full‑year 2025 financial results, scheduled for release on February 26, 2026, and an investor event on March 19, 2026.
Scott A. Smith, Viatris’ CEO, praised Roman’s “many years of dedicated leadership and service” and highlighted the importance of strong legal expertise in building the company. Chief Compliance Officer David Bayles emphasized the company’s commitment to “highest ethical practices and regulatory adherence,” underscoring the central role of the legal and compliance functions in Viatris’ mission to empower people worldwide to live healthier lives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.